Fukushi S, Merola L O, Kinoshita J H
Invest Ophthalmol Vis Sci. 1980 Mar;19(3):313-5.
A potent new aldose reductase (AR) inhibitor was effective in preventing cataractous changes in diabetic rats. Untreated diabetic rats developed early lens changes by 3 weeks and dense nuclear opacities by 6 to 9 weeks. In contrast, diabetic rats treated with the AR inhibitor showed no lens changes during the 5-month period of the experiment.
一种强效的新型醛糖还原酶（AR）抑制剂可有效预防糖尿病大鼠的白内障病变。未经治疗的糖尿病大鼠在3周时出现早期晶状体变化，在6至9周时出现致密的核混浊。相比之下，用AR抑制剂治疗的糖尿病大鼠在实验的5个月期间未出现晶状体变化。
